MBD2 and acute kidney injury: For example, METTL3 can be used as a therapeutic target and as an early diagnostic indicator of kidney diseases such as ischemia‒reperfusion injury (Meng et al. 2020), cisplatin-induced AKI (Wang et al. 2022) and obstructive nephropathy (Liu et al. 2020); the demethylase FTO can be used as a therapeutic target for DN (Sun et al. 2022) and uremia (Wang et al. 2020).